JUVISÉ-PHARMACEUTICALS
26.3.2024 15:10:33 CET | Business Wire | Press release
The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035. To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals. Financial details of these transactions remain undisclosed.
“We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals. “This acquisition is a strategic step for Juvisé as it expands our portfolio with the first patent protected product with strong development potential over the coming years. It is in line with what we have been doing for the past 16 years, which is providing essential medications to patients and specialist doctors. Following our latest partnerships established with Novartis, AstraZeneca and AbbVie, we are proud to establish a new partnership with a major pharmaceutical company and to have two strong partners such as Bpifrance and Pemberton enter our capital to support our future growth.”
The acquisition of Ponvory®: a strategic move in Juvisé Pharmaceuticals' growth strategy
Multiple Sclerosis (MS) is a chronic autoimmune pathology affecting over 2.5 million patients worldwide and enjoys therapeutic innovation.
Ponvory® (ponesimod) is a first-line treatment option in active forms of relapsing multiple sclerosis (RMS), which is the most common form of the disease (approximately 80% of patients), affecting particularly women around the age of 30-years-old. Ponvory® is the first oral Disease Modifying Treatment (DMT) to demonstrate superior efficacy compared to teriflunomide in a large head-to-head Phase III study (OPTIMUM) in adult patients with active RMS. Ponvory® demonstrated a 30.5% reduction in Annualized Relapse Rate (primary endpoint), as well as reduction in MRI activity and fatigue (secondary endpoints). (1)
Juvisé Pharmaceuticals will leverage its expertise in medical affairs, marketing, and distribution to commercialize and develop Ponvory® outside of the United States and Canada, with a focus on Europe, skills that the company has already demonstrated with the successful European relaunch of Pylera® in 2023. Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients. Ponvory® is currently available in 30 countries, with the objective of expanding this scope. Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.
Juvisé Pharmaceuticals opens its capital to Bpifrance and Pemberton
The acquisition of Ponvory® is funded by a mix of capital increase, additional debt, and shareholder loan.
Bpifrance, the French sovereign fund financing businesses in their development, and Pemberton, a leading European private credit manager, have acquired a minority stake in Juvisé as part of the transaction.
About Juvisé Pharmaceuticals
Since its creation in 2008, Juvisé Pharmaceuticals has played a pivotal role in enhancing patient care by providing access to treatments with high medical value. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry, and rheumatology, making them accessible to over 4.4 million patients every year. Juvisé Pharmaceuticals is present through its products in 80 countries in the world on five continents and relocates the production of its acquired medications in Europe, with 81% being manufactured in Europe and 51% in France. In 2024, Juvisé Pharmaceuticals revenues are expected to reach about 180M€ (+38% vs 2023) with PONVORY® accounting for about 24%.
For more information, visit www.juvisepharmaceuticals.com
Lazard acted as financial advisor to Juvisé Pharmaceuticals and its shareholders.
Bird & Bird, Latham & Watkins and Bredin Prat acted as legal counsel to Juvisé Pharmaceuticals.
Société Générale remains the lead banking partner for Juvisé Pharmaceuticals.
1. Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. PMID: 33779698; PMCID: PMC8008435
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325471791/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Names Dirk-Jan "DJ" van Hameren Chief Marketing Officer as Member Base Surpasses 3 Million8.7.2026 13:00:00 CEST | Press release
Former Nike Global CMO and two-time Olympian joins WHOOP amid record global acceleration WHOOP, the human performance company, today named Dirk-Jan "DJ" van Hameren as Chief Marketing Officer. The appointment comes as WHOOP surpasses 3 million members worldwide after adding its latest one million members in just seven months. The former Nike Global Chief Marketing Officer and two-time Olympian joins WHOOP to help build the world's defining global brand for human performance and proactive health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708877245/en/ WHOOP Names Dirk-Jan "DJ" van Hameren (left) Chief Marketing Officer as Member Base Surpasses 3 Million Van Hameren spent more than three decades at Nike, where he rose from the mailroom at the company's European headquarters to become one of the most influential marketing leaders in the world. He served as NIKE Inc.’s Executive Vice President and Chief Marketing Officer
Endace and Artiza Networks Partner to Deliver Cybersecurity and Defense Solutions to the Japanese Market8.7.2026 13:00:00 CEST | Press release
Endace, a leading provider of always-on packet capture, network visibility, and packet forensics solutions, and Artiza Networks, Inc. ("Artiza"), a leading provider of telecommunications test, measurement, and network assurance solutions, today announced a partnership to deliver advanced cybersecurity and defense solutions to customers in Japan. “Artiza is exactly the partner we have been looking for to satisfy demand in Japan, with the right balance of expertise, and market reach,” said Stuart Wilson, CEO of Endace. Through this partnership, Artiza will offer Endace's packet capture, network recording, and packet forensics solutions to customers in Japan, including telecommunications operators, enterprises, government agencies, defense organizations, and critical infrastructure providers. Endace's EndaceProbe Analytics Platform provides highly scalable, always-on packet capture and recording capabilities across a wide range of network environments, including enterprise networks, data
HTEC Introduces “OneLoopAi” Redefining How Enterprises Scale AI Into Production8.7.2026 12:28:00 CEST | Press release
OneLoopAi is the first platform to provide end-to-end transparency between enterprise and partner on AI usage, resource utilization, costs, and value realized. HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and scaled into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708166155/en/ HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and sc
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 10:11:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 10:06:00 CEST | Press release
Joint achievement highlights how Analog In-Memory Computing can address the growing energy and thermal challenges of AI while laying the foundation for deeper collaboration on next-generation memory and computing architectures. TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom